Differentiated thyroid carcinoma

This phase 3 trial tests whether giving recombinant human thyrotropin (rhTSH) injections before radioactive iodine can effectively destroy leftover thyroid tissue after surgery for differentiated thyroid cancer. Normally, patients must stop thyroid hormone medication to raise TSH…

This phase 2 trial tests whether giving recombinant human thyroid stimulating hormone (rhTSH) before radioactive iodine can improve the destruction of leftover thyroid tissue after surgery in people with differentiated thyroid cancer. Participants receive either rhTSH injections …

This study compares two ways of taking the drug pazopanib for people with advanced differentiated thyroid cancer that no longer responds to radioactive iodine. One group takes pazopanib continuously, while the other takes planned breaks and restarts the drug only if the cancer pr…

This study tested whether giving the drug lenvatinib before surgery helps remove advanced thyroid cancer more completely. 29 adults with invasive thyroid cancer took lenvatinib for a short time before their operation. The goal was to see if more patients could have clear or nearl…

This study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…

This study tested the drug cabozantinib in 41 adults with advanced differentiated thyroid cancer that no longer responds to radioactive iodine treatment. Participants took a 60 mg pill daily until their cancer worsened or side effects became too severe. The main goal was to under…

This study tested whether combining targeted drugs (trametinib and dabrafenib) with radioactive iodine can help shrink or control advanced thyroid cancer that has stopped responding to standard radioactive iodine treatment. The trial enrolled 40 adults with specific gene mutation…

This study looked at the safety of the drug lenvatinib in 50 people with advanced thyroid cancer that had stopped responding to radioactive iodine treatment. Researchers tracked side effects and how often patients needed to lower their dose. They also checked whether tumors shran…

This early-phase trial tested an experimental drug called AL2846 in 33 people with a type of thyroid cancer that no longer responds to standard treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Participants took the drug by mouth, and do…

This study looked at 332 people with low-risk papillary thyroid cancer that had spread to neck lymph nodes. Researchers compared robotic surgery (done through small cuts in the armpit and breast) with traditional open surgery. They wanted to see if the robotic method removes canc…

This study tested a new rapid test that checks for thyroid cancer spread to neck lymph nodes in just minutes, instead of the usual days-long wait. Researchers studied 250 adults with suspected or known thyroid cancer, comparing the quick test to standard lab methods. The goal was…

This study looks at whether men and women with a certain type of advanced thyroid cancer (radioiodine-refractory differentiated thyroid cancer) experience different side effects and outcomes when treated with the drug lenvatinib. Researchers will compare dose reductions, side eff…

This study collects standard-of-care images from people with differentiated thyroid cancer who are treated with radioactive iodine (Iodine-131). The goal is to better understand how much radiation reaches healthy organs and what dose is needed to destroy thyroid tissue. By gather…